3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Follicular
3
Fatigue
3
Breast Neoplasms
3
Recurrence
2
Myeloproliferative Disorders
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell, Marginal Zone
2
Lung Neoplasms
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Leukemia, Myeloid, Acute
2
Leukemia, Myeloid, Accelerated Phase
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia
2
Keratosis, Actinic
2
Hodgkin Disease
2
Congenital Abnormalities
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Burkitt Lymphoma
2
Blast Crisis
2
Vomiting
1
Vaginal Neoplasms
1
Interventions
Carboplatin
8
Paclitaxel
7
Hyperthermic Intraperitoneal Chemotherapy
7
Bevacizumab
4
liposomal doxorubicin
3
Gemcitabine
3
Oxaliplatin
2
Neoadjuvant Therapy
2
relacorilant
1
phenoxodiol
1
pembrolizumab
1
oregovomab
1
olaparib
1
nintedanib
1
lobaplatin
1
lanreotide
1
epothilone B
1
atezolizumab
1
Trabectedin
1
Topotecan
1
Therapeutics
1
Surgical Procedures, Operative
1
Saline Solution
1
Leucovorin
1
Letrozole
1
Laparotomy
1
Laparoscopy
1
LAIF 900
1
Hypericum extract LI 160
1
Glucose
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Peritoneal Neoplasms
×
Therapeutics
×
Clear all
NCT02840331
2017-10-27
Hypericin-PDT
University Hospital Tuebingen
Phase 3
Unknown
50 enrolled